
News|Articles|February 1, 2010
Formulary Digital Edition February 2010
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
WeightWatchers Launches Employer Program for GLP-1 Drugs
3
The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
4
Professional Pickleball Players Most Likely to Sustain Eye Injury, Least Likely to Wear Eye Protection, Survey Shows | 2025 AAO
5